Posted by Michael Wonder on 21 Sep 2020
Crinetics Pharmaceuticals receives rare paediatric disease designation from FDA for CRN04777 for the treatment of congenital hyperinsulinism
21 September 2020 - Crinetics Pharmaceuticals today announced that the U.S. Food and Drug FDA has granted rare paediatric disease designation for CRN04777, an investigational, orally available, non-peptide somatostatin receptor type 5 agonist being developed as a treatment for congenital hyperinsulinism.
Congenital hyperinsulinism is a devastating rare disease in which infants are born with life threatening hypoglycemia due to excess insulin secretion.
